On March 2nd, RC017 , an innovative drug developed by Nanjing Ruichu Pharmaceuticals targeting the mechanisms of aging to treat eye diseases , officially received FDA approval for clinical trials in the United States. Notably, this is the first time in FDA history that a Chinese anti-aging innovative drug clinical trial application has been approved.

RC017 is one of the core pipelines of Ruichu Pharmaceuticals, focusing on "targeting aging mechanisms." The company employs a unique "three-platform R&D strategy," focusing on key biological pathways such as chronic inflammation, clearance of senescent cells, and cell reprogramming. Research shows that with age, the common molecular basis of many degenerative diseases converges on chronic inflammatory pathways, and the RC series of drugs is based on the identification and intervention of emerging first-in-class inflammation-related targets.

Founded in June 2021 and headquartered in Nanjing, Ruichu Pharmaceuticals is a leading Chinese company focused on the biology of aging and developing innovative drugs to prevent and reverse aging and related diseases. The company was co-founded by Dr. Ji Yin and Dr. Wang Peng, whose founding team possesses over ten years of research experience in the field of aging and decades of experience in new drug development in both the US and Chinese industries. This dual-engine model of "research + industry" has enabled the company to rapidly build multiple R&D pipelines and advance core projects into clinical trial application stages.

Since its inception, Ruichu Pharmaceuticals has completed multiple rounds of financing , growing against the trend amidst a capital winter. In early 2023, it completed a tens of millions of yuan angel round of financing, jointly invested by Dynamic Balance Capital, Jinyu Maowu, and Nanjing Innovation Investment Group, among others. In May 2024, it announced the completion of a pre-A round of financing exceeding 100 million yuan, led by Longpan Investment, with participation from Delian Capital and Dingxin Capital. In August of the same year, it secured another pre-A+ round of financing with participation from Gaoke Xinjun, the amount of which was not disclosed. This continuous injection of capital has not only accelerated the clinical application process for projects such as RC017 but also reflects the market's high recognition of the anti-aging sector.

Data shows that the global anti-aging market reached $266.2 billion in 2024 and is projected to approach $500 billion by 2032 , with a compound annual growth rate of 8%. China also attaches great importance to the development of this field. In 2024, the State Council issued its first policy document on the "silver economy," explicitly proposing support for the development of the anti-aging industry. As a pioneer in this field in China, Ruichu Pharmaceuticals is leading the way with its original R&D strategies and efficient translation capabilities.

In conclusion , with its strong "scientific research + industrialization" team, Ruichu Pharmaceuticals has successfully advanced its anti-aging drug RC017 to the critical stage of FDA clinical trial approval within less than five years of its establishment, demonstrating its potential to become a world-first drug. Relying on multiple rounds of capital support and national strategic backing, Ruichu Pharmaceuticals has not only achieved its own rapid development but also provided strong support for China to seize the high ground in global anti-aging drug research and development.

https://news.yaozh.com/archive/47339.html